New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthc ...

GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made i ...

Ancora Nominates Director Candidates Despite Elanco's Meaningful Operational Progress and Good Faith Engagement with the Investor GREENFIELD, Ind., Feb. 29, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today issued the following statement in response to the submission of four nominees to the Company's Board of Directors by Ancora Holdings Group, LLC ("Ancora"): The execution of Elanco's Innovation, Portfolio and Productivity strategy, led by CEO Jeff Simmons, is working. Elanco has re ...

Financial Data and Key Metrics Changes - In Q4 2023, the company reported revenue of $1.035 billion, a 5% increase, with price growth of 3% [33] - Full year constant currency revenue growth was 1%, with adjusted EBITDA impacted by approximately $18 million due to unexpected items [6][39] - Adjusted earnings per share for the year was $0.89, down from $1.11 in the previous year, primarily due to higher interest expense and tax [38] Business Line Data and Key Metrics Changes - Farm animal business saw a 4% constant currency revenue growth for the full year, driven by poultry, cattle, and swine [12] - U.S. farm animal business also grew by 4%, with strong performance in cattle and swine [13] - Global pet health revenue declined by 1% in constant currency, showing improvement from a 5% decline in 2022 [14] Market Data and Key Metrics Changes - International pet health revenue declined by 1% in constant currency, primarily due to demand pressure in the Spanish retail market [15] - The U.S. pet health business experienced a 5% decline in Q4, offset by innovation revenue and improved retail inventory [33] - The international farm animal segment delivered 4% constant currency revenue growth, driven by price increases and strong poultry demand in key markets [12] Company Strategy and Development Direction - The company is focused on three priorities for 2024: sustained revenue growth, innovation, and improved cash conversion [5][45] - A strategic restructuring was announced to shift resources from farm animal to pet health, aiming to capitalize on larger markets with greater earnings potential [21] - The company plans to invest in expanding its U.S. pet health field force and enhancing its omnichannel strategy [31][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilient demand for animal care, despite economic conditions impacting consumers and livestock profitability [29] - The outlook for 2024 includes expected revenue growth of 1% to 3%, with innovation contributing significantly to this growth [40] - Management acknowledged competitive pressures in the veterinary clinic market but believes the company is well-positioned due to its innovation pipeline and omnichannel approach [87] Other Important Information - The company announced the sale of its aqua business for approximately $1.3 billion, allowing for a focus on larger markets [50] - Free cash flow is expected to improve significantly in 2024, with approximately $300 million available for debt pay down [9][44] - The company completed its ERP system integration, which is expected to free up over $100 million of cash flow for debt pay down in 2024 [17] Q&A Session Summary Question: What are the approval timelines for Zenrelia in international markets? - Management indicated that there are no changes to the approval timelines and will announce any updates as they occur [72] Question: Can you discuss the go-to-market strategy for Zenrelia? - The company is focused on differentiation and execution, with plans to enhance share of voice and awareness in the veterinary clinic market [76][78] Question: How will the restructuring impact the company's distribution strategy? - The restructuring aims to concentrate resources in strategic areas, transitioning non-strategic markets to a distribution model [102] Question: What is the expected impact of competitive pressures in the veterinary clinics? - Management acknowledged high competition but believes their innovation and omnichannel strategy will help mitigate these pressures [87] Question: Can you clarify the incremental spending related to new product launches? - Incremental spending for new product launches will be additional to the existing operating expenses, but these products are expected to be accretive to EBITDA [82]

Elanco Animal Health Incorporated (ELAN) reported $1.04 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 4.8%. EPS of $0.08 for the same period compares to $0.19 a year ago.The reported revenue represents a surprise of +3.53% over the Zacks Consensus Estimate of $999.74 million. With the consensus EPS estimate being $0.10, the EPS surprise was -20.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

2023 Full Year Results 1Non-GAAP financial measures. See Appendix to this presentation for more information, including GAAP to non-GAAP reconciliations. 2Constant Currency (CC) is a non-GAAP financial measure, representing revenue growth excluding the impact of foreign exchange rates. 3Expected trade name upon approval. $76M of debt paydown in 2023 – expecting ~$300M in 2024; Announced agreement to sell aqua business for ~$1.3B in cash with net proceeds to accelerate debt paydown and deleveraging 2022 to 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2500 INNOVATION WAY, GREENFIELD, INDIANA 46140 (Address an ...

Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results GREENFIELD, IN (February 26, 2024) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2023 and provided initial guidance both for the first quarter and full year 2024. "Elanco ended 2023 with momentum, returning to constant currency revenue growth for the full year and delivering 5% growth in the fourth quarter, primarily driven by our farm animal business, innovatio ...

Wall Street analysts forecast that Elanco Animal Health Incorporated (ELAN) will report quarterly earnings of $0.10 per share in its upcoming release, pointing to a year-over-year decline of 47.4%. It is anticipated that revenues will amount to $999.74 million, exhibiting an increase of 1.2% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessmen ...

Elanco Animal Health Incorporated (ELAN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 26, 2024, might help the stock move higher if these key ...